RLAY relaytx.com: Enterprise Value to EBITDA Ratio

Relay Therapeutics (RLAY) is developing targeted oncology while facing geopolitical risks regarding patent protection and raw material supplies. The EV/EBITDA dynamics for this capital-intensive company on the GURU.Markets daily chart show that the metric stands at 0.00. The team integrates bioinformatics and supercomputing experts, while unique software ensures high drug precision, eliminating price wars with traditional pharmaceutical businesses.

RLAY (Relay Therapeutics Inc) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/10/2026

Comprehensive metric breakdowns and analytics for relaytx.com (RLAY)

- stock price and consensus target price:

Stock Quotes Relay Pharma|RLAY - Average Forecast Price

- company stock capitalization data:

Market Valuation Relay Corp|RLAY - Value Adjusted for Debt and Cash

- business book valuation details:

Accounting Value per Share Relay Therapeutics|RLAY - Total Net Assets|Market Capitalization to Book Value Ratio relaytx.com|RLAY - Company Total Assets

- debt and solvency information:

- net income and valuation multiples indicators:

RLAY - Company Net Income|Projected Future Earnings Relay Therapeutics|RLAY - Price to Earnings Multiple|Projected Price to Earnings Relay Therapeutics|RLAY - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Relay Corp|RLAY - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Relay Therapeutics|RLAY - Earnings per share for the trailing year|Quarterly EPS earnings growth relaytx.com|RLAY - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Relay Therapeutics

Basic company analysis:Relay Pharma RLAY

For the computational drug design innovator Relay Therapeutics (RLAY), this indicator compares the total enterprise value of the business with its operating profit before interest, taxes, depreciation, and amortization. By analyzing fluctuations in the EV/EBITDA multiple, an investor determines the real value of leveraged assets, assessing how the company's market capitalization aligns with its ability to generate cash flow amidst high R&D expenditures.

Competitor analysis

Genmab US - Enterprise Value to EBITDA Ratio|Exelixis Inc. (EXEL) - Company Value to EBITDA|NUVL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation KYMR (kymeratx.com)|IDYA (IDEAYA Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|ELVN: Enterprise Value to Operating Income Before Depreciation Ratio|ORIC (ORIC Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Nurix Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tyra Biosciences, Inc. (TYRA)|VSTM (verastem.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GLUE (Monte Rosa Therapeutics, Inc.)|Enterprise Value to EBITDA Multiple Cullinan Oncology|Immuneering Inc. - EV/EBITDA Multiple|Company Value to EBITDA C4 Therapeutics Corp|BDTX (Black Diamond) - Enterprise Value to EBITDA Ratio|RPTX: Enterprise Value to Operating Income Before Depreciation Ratio|PMVP (PMV Pharmaceuticals, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Karyopharm KPTI|EV/EBITDA Multiple PPCB|Cyclacel - Enterprise Value to Operating Income Before Depreciation|Aadi Bioscience, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ALRN|BPMC: Enterprise Value to EBITDA Ratio|GlycoMimetics, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|SWTX: EV/EBITDA Multiple